Search contract descriptions, companies and agencies.
SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS
Total Committed
$48.9M
Product or Service Description
Biomedical Applied Research/Exploratory Development R&D
Total Potential Value
$48.9M
Contracting Agency
Effective Date
May 1, 2020
Funding Department
OFC ASST SEC FOR PREPARENESS&RES
Type
Cost no fee
Solicitation Procedure
Basic research
Extent Competed
Full and open competition
Recent Contract Actions 
Contracts can have multiple “contract actions”: This is how agencies spend money for a specific purpose, adjust the amount committed or change the contract in a way that doesn’t affect the amount. That last scenario is usually indicated by a $0 action. If there is a contract action for a negative amount, it generally means the contract was adjusted or canceled.
| Vendor | Description | Signed | Reason for Change | Amount Committed |
|---|---|---|---|---|
| MAYO CLINIC | SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS | Aug. 14, 2020 | Supplemental Agreement For Work Within Scope | $0 |
| MAYO CLINIC | SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS | May 11, 2020 | Exercise An Option | $22,432,000 |
| MAYO CLINIC | SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS | May 1, 2020 | $26,495,887 |
About this data
This data comes from the Federal Procurement Data System, which includes all contracts worth $10,000 or more. We look at all contracts that are tagged with the procurement code for COVID-19 or otherwise started in 2020 and contain “COVID-19” in the description. Department of Defense contracting data is subject to a 90-day delay before it appears in the data.